Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 126, Issue 1, 2003, Pages 17-25

  DeCamp, Malcolm M ^a   Rice, Thomas W ^a   Adelstein, David J ^a   Chidel, Mark A ^a   Rybicki, Lisa A ^a   Murthy, Sudish C ^a   Blackstone, Eugene H ^a   Ginsberg, Robert ^b   Mathisen, Douglas J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Cleveland Clinic Foundation ^*

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DRUG FATALITY; DYSPHAGIA; ESOPHAGUS PERFORATION; FEMALE; HEART INFARCTION; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME;

EID: 0042844688     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5223(03)00206-X     Document Type: Article

References (18)

1. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT 3rd, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880-92.
2. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997;15:712-22.
3. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981-9.
4. Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, Van Kirk MA, et al. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg. 1995;60:586-91.
5. Rice TW, Adelstein DJ, Ciezki JP, Becker ME, Rybicki LA, Farver CF, et al. Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer. Ann Thorac Surg. 1998;66:1909-14.
6. Thames HD Jr, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983;9:127-38.
7. Withers HR, Biologic basis for altered fractionation schemes. Cancer. 1985;55:2086-95.
8. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
9. Blackstone EH, Naftel DC, Turner ME Jr. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc. 1986;81:615-24.
10. Kirklin JW, Barratt-Boyes BG. Cardiac surgery. 2nd ed. New York: Churchill Livingstone; 1993. p. 249.
11. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of cancer and leukemia group B protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg. 1995;109:473-83.
12. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-80.
13. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-8.
14. Pitz CC, Maas KW, Van Swieten HA, de la Riviere AB, Hofman P, Schramel FM. Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. Ann Thorac Surg. 2002;74:164-9.
15. Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg. 2001;122:796-802.
16. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-7.
17. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-37.
18. Breiman L. Bagging predictors. Machine Learning. 1996;26:123-40.